Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study

BACKGROUND: Melanoma accounts for only 1% of all skin malignant tumors; however, it is the deadliest form of skin cancer. Since 2011, FDA (Food and Drug Administration) approved several novel therapeutic strategies, such as MAPK pathway targeted therapies, to treat cutaneous melanoma patients. Howev...

Descripción completa

Detalles Bibliográficos
Autores principales: Pópulo, Helena, Domingues, Beatriz, Sampaio, Cristina, Lopes, José Manuel, Soares, Paula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163970/
https://www.ncbi.nlm.nih.gov/pubmed/34079392
http://dx.doi.org/10.2147/JEP.S297831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163970/
https://www.ncbi.nlm.nih.gov/pubmed/34079392
http://dx.doi.org/10.2147/JEP.S297831

Ejemplares similares